Efficacy, tolerability and barriers to the use of anti-CGRP medications among migraine patients in Egypt: real world experience
Clinical Scorecard: Real-World Assessment of Anti-CGRP Therapy Effectiveness, Tolerability, and Access Challenges in Migraine Patients in Egypt
At a Glance
| Category | Detail |
|---|
| Condition | Migraine |
| Key Mechanisms | Anti-CGRP therapies |
| Target Population | Migraine patients in Egypt |
| Care Setting | Descriptive observational study |
Key Highlights
- 68% of patients showed a favorable ≥50% response to anti-CGRP therapy
- Clinically significant reduction in monthly migraine days and headache severity
- Tolerability of anti-CGRP therapies was generally favorable
- Treatment discontinuation occurred in 35 patients, mainly due to cost or lack of improvement
- 42.1% of patients experienced relapse after treatment discontinuation
Guideline-Based Recommendations
Diagnosis
- Assessment using headache diaries, MIDAS, and HIT-6
Management
- Prescribing Erenumab, Galcanezumab, or Rimegepant for migraine treatment
Monitoring & Follow-up
- Follow-up assessments at one and three months post-treatment initiation
Risks
- Relapse rate of 42.1% after drug discontinuation
Patient & Prescribing Data
80 patients (62 chronic and 18 episodic migraine)
Overall clinical improvement and good tolerability observed
Clinical Best Practices
- Evaluate background headache and medication overuse headache pre-and post-treatment
- Monitor reasons for treatment discontinuation
Related Resources & Content
